Clinical Trial Update: Extension Study to VEG105192 to Assess Pazopanib in Patients With Advanced/Metastatic Renal Cell Cancer [Phase 3]

View source ↗

Summary

An extension study of pazopanib (VEG105192) in patients with advanced or metastatic renal cell carcinoma has completed Phase 3 and posted results.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Renal Cell Carcinoma

Drugs mentioned

• Votrient (Pazopanib)

Snippet

Sponsor: GlaxoSmithKline | Conditions: Carcinoma, Renal Cell | Phase 3 | Status: COMPLETED | Results posted: 2013-12-03